Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.57 USD | +0.22% | -0.65% | +7.28% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 283M |
---|---|---|---|---|---|
Net income 2024 * | -101M | Net income 2025 * | -122M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-2.88
x | P/E ratio 2025 * |
-2.86
x | Employees | 59 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.48% |
Latest transcript on Inozyme Pharma, Inc.
1 day | +0.22% | ||
1 week | -0.65% | ||
Current month | +3.63% | ||
1 month | +3.86% | ||
3 months | -19.96% | ||
6 months | +16.28% | ||
Current year | +7.28% |
Managers | Title | Age | Since |
---|---|---|---|
Axel Bolte
FOU | Founder | 52 | 15-08-31 |
Doug Treco Treco
CEO | Chief Executive Officer | 66 | 20-04-30 |
Director of Finance/CFO | 48 | 22-03-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Doug Treco Treco
CEO | Chief Executive Officer | 66 | 20-04-30 |
Reinaldo Diaz
BRD | Director/Board Member | 70 | 16-12-31 |
Axel Bolte
FOU | Founder | 52 | 15-08-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 34 M€ | +4.20% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-24 | 4.57 | +0.22% | 234,398 |
24-05-23 | 4.56 | -2.56% | 312,405 |
24-05-22 | 4.68 | -0.43% | 311,985 |
24-05-21 | 4.7 | -0.63% | 445,306 |
24-05-20 | 4.73 | +2.83% | 306,316 |
Delayed Quote Nasdaq, May 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.28% | 283M | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+45.66% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- INZY Stock